P499: Accessing ultrasonographic transmural healing in patients with Crohn’s disease after induction therapy with infliximab: should we aim for higher infliximab trough levels?ECCO'22Year: 2022
Authors: Morão, B.(1);Frias Gomes, C.(1);Revés, J.(1);Cúrdia Gonçalves, T.(2);Freitas, M.(2);Castro, F.(2);Moreira, M.J.(2);Cotter, J.(2);Pereira, F.(3);Caldeira, A.(3);Sousa, R.(3);Coelho, R.(4);Macedo, G.(4);Macedo, C.(5);Ferreira, M.(5);Glória, L.(1);Torres, J.(1);Palmela, C.(1);
(1)Hospital Beatriz Ângelo, Gastroenterology, Lisbon, Portugal;(2)Hospital da Senhora da Oliveira- Life and Health Sciences Research Institute- School of Medicine- University of Minho- Braga- ICVS/3B’s- PT Government Associate Laboratory, Gastroenterology, Guimarães/Braga, Portugal;(3)Unidade Local de Saúde de Castelo Branco- EPE- Hospital Amato Lusitano, Gastroenterology, Castelo Branco, Portugal;(4)Centro Hospitalar de São João, Gastroenterology, Porto, Portugal;(5)Centro Hospitalar Universitário de Coimbra, Gastroenterology, Coimbra, Portugal;
P501: Vedolizumab is associated with longer drug sustainability compared to infliximab in moderate-to-severe Ulcerative Colitis: a real-world cohort studyECCO'22Year: 2022
Authors: Konikoff, T.(1);Yanai, H.(1);Banai, H.(1);Avni-Biron, I.(1);Snir, Y.(1);Broitman, L.(1);Barkan, R.(1);Checholin, L.(1);Dotan, I.(1);Ollech, J.(2);
(1)Rabin Medical Center- Petah-Tikva- Israel- Sackler Faculty of Medicine- Tel Aviv University- Tel Aviv- Israel, Gastroenterology, petah tikva, Israel;(2)Rabin Medical Center- Petah-Tikva- Israel- Sackler Faculty of Medicine- Tel Aviv University- Tel Aviv- Israel, Gastroenterology, Petach Tikva, Israel;
P502: Different presentation of tuberculosis associated with anti-TNF therapy among patients with Inflammatory Bowel Disease in endemic area: observation from ChinaECCO'22Year: 2022
Authors: Ye, L.(1,2);Wu, L.(3);Tang, J.(4);Mao, R.(5);Cao, Q.(3);
(1)Xiasha Branch of Sir Run Run Shaw Hospital- School of Medicine- Zhejiang University, Department of Gastroenterology, Hangzhou, China;(2)Sir Run Run Shaw Hospital-School of Medicine-Zhejiang University, Inflammatory Bowel Disease Center, Hangzhou, China;(3)Sir Run Run Shaw Hospital- School of Medicine- Zhejiang University, Inflammatory Bowel Disease Center, Hangzhou, China;(4)The Sixth Affiliated Hospital of Sun Yat-sen Universit, Department of Gastroenterology, Guangzhou, China;(5)The First Affiliated Hospital of Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China;
P503: Early TNF-antagonist maintenance therapy results in better outcomes than immunomodulators in paediatric Crohn's disease: A multi-centre prospective cohort studyECCO'22Year: 2022
Authors: Schneider, R.(1,2);Jacobson, K.(3);Huynh, H.(4);Mack, D.(5);Deslandres, C.(6);deBruyn, J.(7);El-Matary, W.(8);Otley, A.(9);Lawrence, S.(3);Wine, E.(4);Sherlock, M.(10);Critch, J.(11);Jantchou, P.(6);Rashid, M.(9);Carroll, M.(4);Bax, K.(12);Seidman, E.(13);Benchimol, E.(1,2);Ricciuto, A.(1,2);Wu, A.(1);Pullenayegum, E.(2);Walters, T.(1);Nguyen, G.(2);Griffiths, A.(1,2);Church, P.(1,2);
(1)The Hospital for Sick Children, SickKids Inflammatory Bowel Disease Centre- Department of Paediatrics, Toronto, Canada;(2)University of Toronto, Institute of Health Policy Management and Evaluation, Toronto, Canada;(3)B.C. Children’s Hospital, Division of Gastroenterology- Hepatology and Nutrition- Department of Paediatrics, Vancouver, Canada;(4)Stollery Children’s Hospital- University of Alberta, Division of Paediatric Gastroenterology and Nutrition- Department of Pediatrics, Edmonton, Canada;(5)Children’s Hospital of Eastern Ontario- University of Ottawa, Inflammatory Bowel Disease Centre- Department of Paediatrics, Ottawa, Canada;(6)Centre hospitalier universitaire Sainte-Justine, Gastroenterology- Hepatology- and Nutrition, Montreal, Canada;(7)Alberta Children’s Hospital- University of Calgary, Pediatric Gastroenterology- Hepatology & Nutrition, Calgary, Canada;(8)Winnipeg Children’s Hospital- Max Rady College of Medicine- University of Manitoba, Paediatric Gastroenterology, Winnipeg, Canada;(9)IWK Health Centre, Division of Gastroenterology- Department of Paediatrics, Halifax, Canada;(10)McMaster Children's Hospital, Division of Gastroenterology- Department of Paediatrics, Hamilton, Canada;(11)Janeway Children’s Health and Rehabilitation Centre, Division of Gastroenterology, Newfoundland, Canada;(12)Children’s Hospital London Health Sciences Centre, Division of Gastroenterology- Hepatology- and Nutrition- Department of Paediatrics, London, Canada;(13)Montreal Children's Hospital- McGill University Health Centre, Division of Gastroenterology and Nutrition, Montreal, Canada;Canadian Children Inflammatory Bowel Disease Network
P504: Prospective analysis of micronutrient status and disease course in Inflammatory Bowel DiseaseECCO'22Year: 2022
Authors: Brownson, E.(1);Saunders, J.(1);Gerasimidis, K.(2);Karafoulidou, Z.(2);Seenan, J.P.(1);Macdonald, J.(1);
(1)NHS Greater Glasgow and Clyde, Gastroenterology, Glasgow, United Kingdom;(2)University of Glasgow, School of Medicine- Dentistry and Nursing, Glasgow, United Kingdom;
P505: Smoking is associated with the development of adverse events of biological therapy in patients with Inflammatory Bowel DiseaseECCO'22Year: 2022
Authors: TheodorakiMD- MA- PhD c, E.(1);Orfanoudaki, E.(2);Foteinogiannopoulou, K.(2);Koutroubakis, I.(2);
(1)University Hospital of Heraklion, Department of Gastroenterology, Heraklion, Greece;(2)University Hospital of Heraklion- School of Medicine, Department of Gastroenterology, Heraklion, Greece;
P506: Rates of clinical remission among patients with Ulcerative Colitis from real-world clinical practice settings from GermanyECCO'22Year: 2022
Authors: Bokemeyer, B.(1);Picker, N.(2);Kromer, D.(2);Rosin, L.(3);Patel, H.(4);
(1)Gastroenterology Practice, Minden, Minden, Germany;(2)Ingress Health HWM, GmbH, Wismar, Germany;(3)Galapagos Biopharma Deutschland, GmbH, München, Germany;(4)Galapagos, Nv, Mechelen, Belgium;
P507: Need for surgery in patients with ulcerative colitis in the era of biologic therapy.ECCO'22Year: 2022
Authors: Zamora Olaya, J.M.(1);Aparicio-Serrano, A.(1);Gómez Pérez, A.(1);Ortiz Chimbo, D.S.(1);Rodríguez Tirado, M.I.(1);Soto Escribano, P.(1);Marín Pedrosa, S.(1);Iglesias Flores, E.(1);Benítez, J.M.(1);
(1)Reina Sofía University Hospital, Gastroenterology and Hepatology, Córdoba, Spain;IMIBIC
P508: The impact of disease duration and early biologic treatment on transmural healing in Crohn’s diseaseECCO'22Year: 2022
Authors: Revés, J.(1);Freire, G.(2);Sousa, P.(2);Primitivo, A.(2);Nascimento, C.(1);Morão, B.(1);Abreu, N.(3);Palmela, C.(1);Glória, L.(1);Torres, J.(1);
(1)Hospital Beatriz Ângelo, Gastrenterology Department, Loures, Portugal;(2)Hospital Beatriz Ângelo, Radiology Department, Loures, Portugal;(3)Hospital Dr. Nélio Mendonça, Gastrenterology Department, Funchal, Portugal;
P509: Biomarkers of neutrophil activity and extracellular matrix turnover predict long-term response to vedolizumab in patients with Crohn’s diseaseECCO'22Year: 2022
Authors: Sorokina Alexdóttir , M.(1);Bourgonje , A.R.(2);Karsdal , M.A.(1);Bay-Jensen , A.C.(1);Pehrsson , M.(1);Loveikyte , R.(2);van Dullemen , H.M.(2);Visschedijk , M.C.(2); A. M. Festen , E.(2);K. Weersma , R.(2);Faber , K.N.(2);Dijkstra , G.(2);Joachim H. , M.(1);
(1)Nordic Bioscience, Immunoscience, Herlev, Denmark;(2)University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands;
P510: Comparative efficacy of biologic therapies for inducing response and remission in fistulizing Crohn’s disease; Systematic Review and Network Meta-analysisECCO'22Year: 2022
Authors: Shehab, M.(1);Alrashed, F.(2);Heron, V.(3);Restellini, S.(4);Bessissow, T.(5);
(1)Mubarak Alkaber University Hospital, Internal medicine, Aljabreyah, Kuwait;(2)Massachusetts College of Pharmacy and Health Sciences, Public health, Boston, United States;(3)University of Montreal, Gastroenterology, Montreal, Canada;(4)University of Geneva, Internal medicine, Geneva, Switzerland;(5)McGill University, Internal medicine, Montreal, Canada;
P511: Efficacy of Crohn's Disease exclusion diet in different clinical scenarios in paediatrics; at onset of the disease and after loss of response to biological therapyECCO'22Year: 2022
Authors: Jijón, M.C.(1);Pujol-Muncunill, G.(1);Lozano Ruf, A.(1);Vila Miravet, V.(1);Alvarez Carnero, L.(1);García Arenas, D.(1);Egea Castillo, N.(1);Martín de Carpi, J.(1);
(1)Hospital Sant Joan de Deu, Paediatric Gastroenterology- Hepatology- and Nutrition, Barcelona, Spain;
P512: Vedolizumab is effective in the prevention and treatment of postoperative recurrence in patients with Crohn´s diseaseECCO'22Year: 2022
Authors: Kadleckova, B.(1);Podmanicky, D.(2);Lipovska, A.(1);Zelinkova, Z.(1);
(1)St. Michael`s Hospital, Department of Gastroenterology&Digestive Endoscopy, Bratislava, Slovakia;(2)St. Michael`s Hospital, Surgery, Bratislava, Slovakia;
P513: Treatment persistence in bio-naive patients with long-standing Crohn's disease treated with first-line biologics: real-life data from a Croatian tertiary center.ECCO'22Year: 2022
Authors: Biscanin, A.(1);Tomasic, V.(1);Babic, F.(2);Dorosulic, Z.(1);Kralj, D.(1);Cacic, P.(1);Ogresta, D.(1);Hrabar, D.(1);
(1)University Hospital Centre Sestre Milosrdnice, Department of Internal Medicine, Zagreb, Croatia;(2)Zagreb Emergency Medicine Service, Emergency Medicine, Zagreb, Croatia;
P515: Inflammatory bowel disease and malignancy – the outcome of patients with malignancy diagnosed before IBD diagnosis or IBD-targeted therapyECCO'22Year: 2022
Authors: Shani, U.(1);Klang, E.(2);Ungar, B.(3);Ben-Horin, S.(3);Kopylov, U.(3);
(1)Tel-HaShomer Sheba Medical Center, Internal Medicine F, Ramat Gan, Israel;(2)Tel-HaShomer Sheba Medical Center, arc, Ramat Gan, Israel;(3)Tel-HaShomer Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel;
P516: Discrete choice experiment to examine patient preferences for surgical interventions in patients with Crohn’s perianal fistulas: results from a global burden of illness studyECCO'22Year: 2022
Authors: Karki, C.(1);Athavale, A.(2);Hantsbarger, G.(3);Lee, K.(4);Milicevic, S.(5);Perovic, M.(6);Raven, L.(7);Sajak-Szczerba, M.(8);Abilash, V.(2);Tozer, P.(9);
(1)Takeda Pharmaceuticals USA Inc., Global Evidence and Outcomes, Cambridge- MA, United States;(2)Trinity Partners- LLC, Insights & Analytics, Waltham- MA, United States;(3)Takeda Pharmaceuticals USA Inc., Safety and Health Value Statistics, Cambridge- MA, United States;(4)Crohn's & Colitis Canada, Research & Patient Programs, Toronto, Canada;(5)Takeda Pharmaceuticals International AG, GI Rare Medical Affairs, Zurich, Switzerland;(6)European Federation of Crohn’s and Ulcerative Colitis Associations, European Federation of Crohn and Ulcerative Colitis Associations, Brussels, Belgium;(7)Crohn's & Colitis Australia, n/a, Camberwell, Australia;(8)European Federation of Crohn’s and Ulcerative Colitis Associations, n/a, Brussels, Belgium;(9)St. Mark’s Hospital and Academic Institute, Fistula Research Unit, London, United Kingdom;
P517: Re-treatment with filgotinib in patients with Ulcerative Colitis following treatment interruption: Analysis of the SELECTION and SELECTIONLTE studiesECCO'22Year: 2022
Authors: Vermeire, S.(1);Feagan, B.(2,3);Peyrin-Biroulet, L.(4);Oortwijn, A.(5);Faes, M.(6);de Haas, A.(5);Rogler, G.(7);
(1)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(2)Alimentiv, Inc., London Ontario, Canada;(3)London Health Sciences Centre- Western University, Division of Gastroenterology, London Ontario, Canada;(4)University Hospital of Nancy- University of Lorraine, Department of Gastroenterology, Vandoeuvre-lès-Nancy, France;(5)Galapagos, Nv, Leiden, The Netherlands;(6)Galapagos, Nv, Mechelen, Belgium;(7)University Hospital Zurich- University of Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland;
P518: Partial enteral nutrition use for Crohn’s disease management: a systematic reviewECCO'22Year: 2022
Authors: Jatkowska, A.(1);White, B.(1);Gkikas, K.(1);Seenan, J.P.(2);MacDonald, J.(2);Gerasimidis, K.(1);
(1)University of Glasgow, Human Nutrition, Glasgow, United Kingdom;(2)Queen Elizabeth University Hospital, Department of Gastroenterology, Glasgow, United Kingdom;
